Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 11, 2006

Cephalon Inks Deal to Enter the Chinese Market

  • Beijing Med-Pharm will help Cephalon introduce its products in China. Beijing Med-Pharm will undertake clinical development and the registration process. The initial focus of the agreement will be Fentora™, which was approved in September, 2006, for the management of breakthrough pain in patients with cancer who are already receiving and are tolerant to opioid therapy.

    The Chinese State Food and Drug Administration accepts registration of U.S.-approved pharmaceuticals after one clinical trial is conducted in China. Beijing Med-Pharm will thus design and conduct a Chinese registration trial for Fentora. The companies expect the application process to commence in 2007.

    "Beijing Med-Pharm has developed contacts in the oncology community in China and a full suite of capabilities for investigating and registering Western medicines in this significant and rapidly growing market,” says Robert P. Roche, executive vp, worldwide pharmaceutical operations at Cephalon. “We intend for our collaboration on Fentora to be the first in a successful partnership with Beijing Med-Pharm that will facilitate the incorporation of Cephalon products into medical care in China."

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »